Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management - PubMed

Affiliations

• PMID: 25816717
• DOI: 10.1111/jth.12916

Free article

Review

Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management

A Casini et al. J Thromb Haemost. 2015 Jun.

Free article

Abstract

Congenital dysfibrinogenemia is a qualitative congenital fibrinogen disorder characterized by normal antigen levels of a dysfunctional fibrinogen. The diagnosis is usually based on discrepancies between fibrinogen activity and antigen levels, but could require more specialized techniques for the assessment of fibrinogen function, owing to some limitations in routine assays. Molecular abnormalities, which are frequently heterozygous missense mutations localized in exon 2 of FGA and exon 8 of FGG, lead to defects in one or more phases of fibrinogen to fibrin conversion, fibrin network formation, and other important functions of fibrinogen. The clinical phenotype is highly heterogeneous, from no manifestations to bleeding and/or thrombotic events. Asymptomatic propositi and relatives with the predisposing genotype are at risk of developing adverse outcomes during the natural course of the disease. Correlations between genotype and phenotype have not yet been clearly established, with the exception of some abnormal fibrinogens that severely increase the risk of thrombosis. Functional analysis of polymerization and fibrinolysis, structural studies of the fibrin network and the viscoelastic properties of fibrin clot could help to predict the phenotype of congenital dysfibrinogenemia, but have not yet been evaluated in detail. The management is essentially based on personal and family history; however, even individuals who are still asymptomatic and without a family history should be carefully assessed and monitored. Particular situations, such as pregnancy, delivery, and surgery, require a multidisciplinary approach.

Keywords: bleeding; congenital; dysfibrinogenemia; fibrinogen; pregnancy; thrombosis.

Similar articles

• Diagnosis of congenital fibrinogen disorders.

  Lebreton A, Casini A. Lebreton A, et al. Ann Biol Clin (Paris). 2016 Aug 1;74(4):405-12. doi: 10.1684/abc.2016.1167. Ann Biol Clin (Paris). 2016. PMID: 27492693 Review. English.

• Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen.

  Haverkate F, Samama M. Haverkate F, et al. Thromb Haemost. 1995 Jan;73(1):151-61. Thromb Haemost. 1995. PMID: 7740487 Review.

• Three cases of congenital dysfibrinogenemia in unrelated Chinese families: heterozygous missense mutation in fibrinogen alpha chain Argl6His.

  Luo M, Deng D, Xiang L, Cheng P, Liao L, Deng X, Yan J, Lin F. Luo M, et al. Medicine (Baltimore). 2016 Sep;95(39):e4864. doi: 10.1097/MD.0000000000004864. Medicine (Baltimore). 2016. PMID: 27684817 Free PMC article.

• Management of dysfibrinogenemia in pregnancy: A case report.

  Yan J, Deng D, Cheng P, Liao L, Luo M, Lin F. Yan J, et al. J Clin Lab Anal. 2018 Mar;32(3):e22319. doi: 10.1002/jcla.22319. Epub 2017 Sep 26. J Clin Lab Anal. 2018. PMID: 28948631 Free PMC article.

• Congenital dysfibrinogenemia in major surgery: A description of four cases and review of the literature.

  Yan J, Luo M, Xiang L, Wu Y, Lin F. Yan J, et al. Clin Chim Acta. 2022 Mar 1;528:1-5. doi: 10.1016/j.cca.2022.01.009. Epub 2022 Jan 19. Clin Chim Acta. 2022. PMID: 35063457 Review.

Cited by

• Bioactive Natural Compounds with Antiplatelet and Anticoagulant Activity and Their Potential Role in the Treatment of Thrombotic Disorders.

  Lamponi S. Lamponi S. Life (Basel). 2021 Oct 15;11(10):1095. doi: 10.3390/life11101095. Life (Basel). 2021. PMID: 34685464 Free PMC article. Review.

• Identification of novel mutations in congenital afibrinogenemia patients and molecular modeling of missense mutations in Pakistani population.

  Naz A, Biswas A, Khan TN, Goodeve A, Ahmed N, Saqlain N, Ahmed S, Ujjan ID, Shamsi TS, Oldenburg J. Naz A, et al. Thromb J. 2017 Sep 12;15:24. doi: 10.1186/s12959-017-0143-3. eCollection 2017. Thromb J. 2017. PMID: 28912669 Free PMC article.

• Fibrinogen BOE II: dysfibrinogenemia with bleeding and defective thrombin binding.

  Li Y, Liang Q, Wu W, Hu X, Wang H, Wang X, Ding Q. Li Y, et al. Res Pract Thromb Haemost. 2023 Jul 7;7(5):102145. doi: 10.1016/j.rpth.2023.102145. eCollection 2023 Jul. Res Pract Thromb Haemost. 2023. PMID: 37601017 Free PMC article.

• Fibrinogen Longmont: A Clinically Heterogeneous Dysfibrinogenemia with Discrepant Fibrinogen Results Influenced by Clot Detection Method and Reagent.

  Leung B, Beggs J, Mason J. Leung B, et al. TH Open. 2022 Jan 24;6(1):e18-e20. doi: 10.1055/s-0041-1740644. eCollection 2022 Jan. TH Open. 2022. PMID: 35088022 Free PMC article. No abstract available.

• Fibrin Formation, Structure and Properties.

  Weisel JW, Litvinov RI. Weisel JW, et al. Subcell Biochem. 2017;82:405-456. doi: 10.1007/978-3-319-49674-0_13. Subcell Biochem. 2017. PMID: 28101869 Free PMC article. Review.

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.
  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Miscellaneous

  • NCI CPTAC Assay Portal